The Impact of Arteriovenous Fistulae on the Myocardium

The Impact of Creation and Ligation in the Transplant Era

Juan Camilo Duque, Camilo Gomez, Marwan Tabbara, Carlos E Alfonso, Xiaoyi Li, Roberto I Vazquez-Padron, Arif Asif, Oliver Lenz, Patricia Briones, Loay Salman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cardiac hypertrophy is a relatively common complication seen in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD). Moreover, cardiac hypertrophy is even more frequently seen in patients with ESRD who have an arteriovenous (AV) access. There has been substantial evidence pertaining to the effects of AV access creation on the heart structure and function. Similarly, there is increasing evidence on the effects of AV access closure, flow reduction, transplantation, and immunosuppressive medication on both endpoints. In this review, we present the evidence available in the literature on these topics and open the dialog for further research in this interesting field.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalSeminars in Dialysis
Volume28
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

Arteriovenous Fistula
Cardiomegaly
Chronic Kidney Failure
Ligation
Myocardium
Transplants
Immunosuppressive Agents
Chronic Renal Insufficiency
Transplantation
Research

ASJC Scopus subject areas

  • Nephrology

Cite this

The Impact of Arteriovenous Fistulae on the Myocardium : The Impact of Creation and Ligation in the Transplant Era. / Duque, Juan Camilo; Gomez, Camilo; Tabbara, Marwan; Alfonso, Carlos E; Li, Xiaoyi; Vazquez-Padron, Roberto I; Asif, Arif; Lenz, Oliver; Briones, Patricia; Salman, Loay.

In: Seminars in Dialysis, Vol. 28, No. 3, 01.05.2015, p. 305-310.

Research output: Contribution to journalArticle

@article{478bc1b449964a5f9903b7a54f0a41ef,
title = "The Impact of Arteriovenous Fistulae on the Myocardium: The Impact of Creation and Ligation in the Transplant Era",
abstract = "Cardiac hypertrophy is a relatively common complication seen in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD). Moreover, cardiac hypertrophy is even more frequently seen in patients with ESRD who have an arteriovenous (AV) access. There has been substantial evidence pertaining to the effects of AV access creation on the heart structure and function. Similarly, there is increasing evidence on the effects of AV access closure, flow reduction, transplantation, and immunosuppressive medication on both endpoints. In this review, we present the evidence available in the literature on these topics and open the dialog for further research in this interesting field.",
author = "Duque, {Juan Camilo} and Camilo Gomez and Marwan Tabbara and Alfonso, {Carlos E} and Xiaoyi Li and Vazquez-Padron, {Roberto I} and Arif Asif and Oliver Lenz and Patricia Briones and Loay Salman",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/sdi.12313",
language = "English (US)",
volume = "28",
pages = "305--310",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The Impact of Arteriovenous Fistulae on the Myocardium

T2 - The Impact of Creation and Ligation in the Transplant Era

AU - Duque, Juan Camilo

AU - Gomez, Camilo

AU - Tabbara, Marwan

AU - Alfonso, Carlos E

AU - Li, Xiaoyi

AU - Vazquez-Padron, Roberto I

AU - Asif, Arif

AU - Lenz, Oliver

AU - Briones, Patricia

AU - Salman, Loay

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Cardiac hypertrophy is a relatively common complication seen in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD). Moreover, cardiac hypertrophy is even more frequently seen in patients with ESRD who have an arteriovenous (AV) access. There has been substantial evidence pertaining to the effects of AV access creation on the heart structure and function. Similarly, there is increasing evidence on the effects of AV access closure, flow reduction, transplantation, and immunosuppressive medication on both endpoints. In this review, we present the evidence available in the literature on these topics and open the dialog for further research in this interesting field.

AB - Cardiac hypertrophy is a relatively common complication seen in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD). Moreover, cardiac hypertrophy is even more frequently seen in patients with ESRD who have an arteriovenous (AV) access. There has been substantial evidence pertaining to the effects of AV access creation on the heart structure and function. Similarly, there is increasing evidence on the effects of AV access closure, flow reduction, transplantation, and immunosuppressive medication on both endpoints. In this review, we present the evidence available in the literature on these topics and open the dialog for further research in this interesting field.

UR - http://www.scopus.com/inward/record.url?scp=84929606760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929606760&partnerID=8YFLogxK

U2 - 10.1111/sdi.12313

DO - 10.1111/sdi.12313

M3 - Article

VL - 28

SP - 305

EP - 310

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 3

ER -